Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Market Cap	13.25B -71.8%
Revenue (ttm)	34.37M -7.7%
Net Income	-370.06M
EPS	-2.23
Shares Out	167.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,939
Open	79.50
Previous Close	81.30
Day's Range	79.00 - 80.50
52-Week Range	73.70 - 319.50
Beta	0.07
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the compa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 36
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 12, 2026

Data Sources Report a data error